Status:

TERMINATED

Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

Lead Sponsor:

Buddhist Tzu Chi General Hospital

Conditions:

Parkinson Disease

Eligibility:

All Genders

40-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the effectiveness of neuroprotection from granulocyte colony-stimulating factor on Parkinson disease

Detailed Description

Parkinson's disease (PD) is the second most common neurodegenerative disease and the severity of PD still progress during the ensuing years. Currently, there is no promising medical or surgical treatm...

Eligibility Criteria

Inclusion

  • Hoehn \& Yahr stage I\~III
  • Patients with idiopathic Parkinson's disease(PD), who meet the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria, with a good response to levodopa
  • The onset of PD symptoms must be occurred \> = 40 years of age (to exclude YOPD), and the patient must have been diagnosed with idiopathic PD \> =40 years of age
  • Patients may have symptoms of wearing OFF and/or levodopa induced dyskinesia
  • Patients must rate between Hoehn \& Yahr stage I to III, when in an OFF medication state
  • Patients must in their optimal medication treatment state, and will not changing their medications within 3 months before and after enrollment

Exclusion

  • Patients who are proved to be Young Onset Parkinson's Disease (YOPD) and/or genetically related (e.g. Parkin).
  • Women of child-bearing potential, pregnant or lactating.
  • Patients who are proved to have tumor growth and/or malignancy.
  • Patients with a past (within one year) or present history of psychotic symptoms requiring anti- psychotic treatment.
  • Patients with active symptoms of major depression with suicidal ideation or suicide attempt.
  • Patients with previous brain surgery (including pallidotomy and deep brain stimulation).
  • Patients with significant cognitive impairment ( Mini-Mental State Examination, MMSE \< 24).
  • Patients who do not sign the inform consent,

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT01227681

Start Date

June 1 2010

End Date

December 1 2013

Last Update

April 4 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Buddhist Tzu Chi General Hospital

Hualien City, Taiwan

Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease | DecenTrialz